Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Advisor Hasegawa, Herald of Takeda Globalization, Steps Down
July 1, 2019
- Ayumi Taps Kiyonori Karasawa as New Chief
June 28, 2019
- Takeda CEO Takes Home 1.75 Billion Yen in FY2018
June 28, 2019
- Japan OKs Companion Diagnostic for Rozlytrek: Chugai
June 28, 2019
- Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
June 28, 2019
- Takeda Vows 4.6 Billion Yen Commitment to Support Disease Prevention in Developing and Emerging Nations
June 27, 2019
- Ono Grabs Rights to US Biotech’s Metabolic Cancer Drug
June 26, 2019
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Daiichi Sankyo to Return Rights to 4 Diagnostic Imaging Agents to GE Healthcare
June 26, 2019
- Opdivo Shows No Significant Difference vs Sorafenib in OS for 1st-Line HCC Use in Global PIII: BMS
June 26, 2019
- MSD’s Zerbaxa Now Available in Japan 4 Months after NHI Price Listing; Ensuring Stable Supply
June 26, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
- Shionogi Hooks Up with Ferrer to Promote Rizmoic in Spain
June 25, 2019
- Shionogi Licenses Mulpleta, Epertinib to China’s Eddingpharm Group
June 25, 2019
- 2018 Global Pharma Market Valued at US$1.09 Trillion, Humira Resounding No. 1: IQVIA
June 24, 2019
- ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
- Ex-Otsuka Kagaku Exec Becomes PeptiStar’s New President
June 24, 2019
- Lantus/Lyxumia Combo Shows Effectiveness in Japan PIII: Sanofi
June 21, 2019
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Japan IBD Market Projected at 155.8 Billion Yen in 2027: Fuji Keizai
June 20, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…